P Vermylen
Overview
Explore the profile of P Vermylen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mascaux C, Martin B, Paesmans M, Verdebout J, Verhest A, Vermylen P, et al.
Anticancer Res
. 2002 Aug;
22(2B):1273-7.
PMID: 12168937
Objective: Initially considered as an inhibitor of angiogenesis, the role of thrombospondin is currently controversial. The primary purpose of our study was to determine the expression of thrombospondin (TSP) in...
2.
Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al.
Nat Genet
. 2001 May;
28(2):131-8.
PMID: 11381259
Hypoxia stimulates angiogenesis through the binding of hypoxia-inducible factors to the hypoxia-response element in the vascular endothelial growth factor (Vegf) promotor. Here, we report that deletion of the hypoxia-response element...
3.
Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte J, Lemaitre F, et al.
Lung Cancer
. 2000 Sep;
30(1):23-36.
PMID: 11008007
Purpose: Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic drugs for small cell lung cancer (SCLC). The present systematic review had as its objective the evaluation of their...
4.
Martinet N, Alla F, Farre G, Labib T, Drouot H, Vidili R, et al.
Cancer Res
. 2000 Jun;
60(11):2869-75.
PMID: 10850430
Smoking prevention will decrease lung cancer incidence in time. However, early detection would improve lung cancer prognosis in subjects at risk provided that specific markers could be identified. We previously...
5.
Pierard P, Vermylen P, Bosschaerts T, Roufosse C, Berghmans T, Sculier J, et al.
Chest
. 2000 Mar;
117(3):779-85.
PMID: 10713006
Objective: To assess the prevalence of synchronous roentgenographically occult lung carcinoma (ROLC) in patients with resectable roentgenographically visible lung cancer (RVLC). Methods: Patients undergoing surgery for RVLC in the same...
6.
Meert A, Berghmans T, Branle F, Lemaitre F, Mascaux C, Rubesova E, et al.
Anticancer Res
. 2000 Jan;
19(5C):4379-90.
PMID: 10650780
We carried out a systematic review of new drugs active in non-small cell lung carcinoma (NSCLC). Fifty five phase II and III trials were reviewed (vinorelbine (19 trials), paclitaxel (15),...
7.
Vermylen P, Roufosse C, Burny A, Verhest A, Bosschaerts T, Pastorekova S, et al.
Eur Respir J
. 1999 Nov;
14(4):806-11.
PMID: 10573225
The MaTu interval (MN)/carbonic anhydrase (CA) IX tumour-associated antigen is a protein that is normally expressed in the gut and belongs to the carbonic anhydrase enzyme family (CA IX). It...
8.
Vermylen P, Pierard P, Roufosse C, Bosschaerts T, Verhest A, Sculier J, et al.
Lung Cancer
. 1999 Oct;
25(3):161-8.
PMID: 10512126
Background: Autofluorescence bronchoscopy (AB) enhances the bronchoscopist's ability to diagnose bronchial preneoplastic lesions and early cancer. We undertook a study to assess its feasibility and performance under local anaesthesia on...
9.
Luce S, Paesmans M, Berghmans T, Castaigne C, Sotiriou C, Vermylen P, et al.
Rev Mal Respir
. 1998 Dec;
15(5):633-41.
PMID: 9834991
The role of chest irradiation in the treatment of small cell lung cancer remains controversial. Two meta-analyses have shown a significant improvement of survival when this therapy is associated to...
10.
Berghmans T, Castaigne C, Luce S, Sotiriou C, Vermylen P, Paesmans M, et al.
Rev Pneumol Clin
. 1998 Oct;
54(3):119-22.
PMID: 9769997
The role of maintenance chemotherapy in the treatment of small cell lung cancer remains controversial. We have collected the arguments in favor of that approach by performing a quantitative and...